| Literature DB >> 35579952 |
Yvonne L Latour1,2, Johanna C Sierra2,3, Jordan L Finley2, Mohammad Asim2, Daniel P Barry2, Margaret M Allaman2, Thaddeus M Smith2, Kara M McNamara2,4, Paula B Luis5, Claus Schneider3,5, Justin Jacobse1,2, Jeremy A Goettel1,2,3, M Wade Calcutt6, Kristie L Rose6, Kevin L Schey6, Ginger L Milne7, Alberto G Delgado2, M Blanca Piazuelo2,3, Bindu D Paul8,9, Solomon H Snyder8,9,10, Alain P Gobert2,3, Keith T Wilson1,2,3,4,11.
Abstract
Macrophages play a crucial role in the inflammatory response to the human stomach pathogen Helicobacter pylori, which infects half of the world's population and causes gastric cancer. Recent studies have highlighted the importance of macrophage immunometabolism in their activation state and function. We have demonstrated that the cysteine-producing enzyme cystathionine γ-lyase (CTH) is upregulated in humans and mice with H. pylori infection. Here, we show that induction of CTH in macrophages by H. pylori promoted persistent inflammation. Cth-/- mice had reduced macrophage and T cell activation in H. pylori-infected tissues, an altered metabolome, and decreased enrichment of immune-associated gene networks, culminating in decreased H. pylori-induced gastritis. CTH is downstream of the proposed antiinflammatory molecule, S-adenosylmethionine (SAM). Whereas Cth-/- mice exhibited gastric SAM accumulation, WT mice treated with SAM did not display protection against H. pylori-induced inflammation. Instead, we demonstrated that Cth-deficient macrophages exhibited alterations in the proteome, decreased NF-κB activation, diminished expression of macrophage activation markers, and impaired oxidative phosphorylation and glycolysis. Thus, through altering cellular respiration, CTH is a key enhancer of macrophage activation, contributing to a pathogenic inflammatory response that is the universal precursor for the development of H. pylori-induced gastric disease.Entities:
Keywords: Amino acid metabolism; Gastroenterology; Immunology; Innate immunity; Macrophages
Mesh:
Substances:
Year: 2022 PMID: 35579952 PMCID: PMC9309056 DOI: 10.1172/jci.insight.155338
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708